



Expression of ERCC1, Bcl-2, MT and their Clinical Significance in Advanced Non-small-cell Lung Cancer Treated With Cisplatin-based Chemotherapy

Haiqing MA^{1,3}, Huanhuan SUN², Fuxi HUANG³, Jing LI⁴, Xiaolong CAO^{3*} & Wenqi JIANG⁵

¹ *State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-sen University Cancer Center, 561 Dongfeng East Road, Guangzhou, Guangdong, 510060, People's Republic of China*

² *Department of Pharmacology, Sun Yat-sen University, 74 Zhongshan Road, Guangzhou, Guangdong, 510080, People's Republic of China*

³ *Department of Medical Oncology and* ⁴ *Department of Pathology, Panyu People's Hospital, 93 Qiaodong Road, Panyu, Guangzhou, 511400, People's Republic of China*

SUMMARY. The aim of this study was to determine the prognostic value of expression of Excision Repair Cross-complementation Group 1 (ERCC1), B cell lymphoma/leukemia-2 (Bcl-2) and metallothionein (MT) by immunohistochemically staining tumor specimens from 78 patients with advanced non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. The result showed that positive expression of ERCC1 was associated both with short survival (10.45 months vs. 14.38 months, log-rank $p = 0.003$) and poor response to cisplatin-based chemotherapy ($p = 0.003$) when compared with negative group. But expression of Bcl-2 and MT was not associated with response to chemotherapy and survival. Multivariate analysis confirmed that expression of ERCC1 was an independent variable related to overall survival ($p = 0.013$). These data support the role of ERCC1 expression as a candidate predictor for the survival of patients with advanced NSCLC treated with cisplatin-based chemotherapy.

KEY WORDS: Bcl-2, Cisplatin, ERCC1, MT, NSCL, Resistance

* Authors to whom correspondence should be addressed. *E-mail:* xiaolong_cao10@163.com.

H. Ma and H. Sun contributed equally to this work.